lunes, 20 de mayo de 2013

Multiplex newborn screening for Pompe, Fabry,... [Clin Chim Acta. 2013] - PubMed - NCBI

Multiplex newborn screening for Pompe, Fabry,... [Clin Chim Acta. 2013] - PubMed - NCBI

Clin Chim Acta. 2013 May 7. pii: S0009-8981(13)00195-2. doi: 10.1016/j.cca.2013.05.001. [Epub ahead of print]

Multiplex newborn screening for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases using a digital microfluidic platform.


Advanced Liquid Logic, Inc., P.O. Box 14025, Research Triangle Park, NC 27709, USA.



New therapies for lysosomal storage diseases (LSDs) have generated interest in screening newborns for these conditions. We present performance validation data on a digital microfluidic platform that performs multiplex enzymatic assays for Pompe, Fabry, Hunter, Gaucher, and Hurler diseases.


We developed an investigational disposable digital microfluidic cartridge that uses a single dried blood spot (DBS) punch for performing a 5-plex fluorometric enzymatic assay on up to 44 DBS samples. Precision and linearity of the assays were determined by analyzing quality control DBS samples; clinical performance was determined by analyzing 600 presumed normal and known affected samples (12 for Pompe, 7 for Fabry and 10 each for Hunter, Gaucher and Hurler).


Overall coefficient of variation (CV) values between cartridges, days, instruments, and operators ranged from 2 to 21%; linearity correlation coefficients were ≥0.98 for all assays. The multiplex enzymatic assay performed from a single DBS punch was able to discriminate presumed normal from known affected samples for 5 LSDs.


Digital microfluidic technology shows potential for rapid, high-throughput screening for 5 LSDs in a newborn screening laboratory environment. Sample preparation to enzymatic activity on each cartridge is less than 3h.
Copyright © 2013. Published by Elsevier B.V.


[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario